Scarica l'app Stockscreener
7.415
2.18%
-0.165
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Precedente Chiudi:
$7.58
Aprire:
$7.48
Volume 24 ore:
6.34M
Relative Volume:
1.00
Capitalizzazione di mercato:
$2.95B
Reddito:
$64.60M
Utile/perdita netta:
$-377.75M
Rapporto P/E:
-5.3732
EPS:
-1.38
Flusso di cassa netto:
$-335.64M
1 W Prestazione:
+25.89%
1M Prestazione:
+15.86%
6M Prestazione:
-13.68%
1 anno Prestazione:
+0.34%
Intervallo 1D:
$7.275
$7.66
Intervallo di 1 settimana:
$5.93
$7.98
Portata 52W:
$5.60
$15.74
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Nome
Recursion Pharmaceuticals Inc
Settore
Industria
Telefono
(385) 269-0203
Indirizzo
41S RIO GRANDE STREET, SALT LAKE CITY
Confronta RXRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
7.415 | 2.95B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.10 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.00 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.82 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.28 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.28 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-05-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Iniziato | Needham | Buy |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-04 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Iniziato | Berenberg | Buy |
| 2021-05-11 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Iniziato | JP Morgan | Neutral |
| 2021-05-11 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
NVIDIA Invested in These 2 AI Stocks, Should You? - MarketBeat
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 8.6%Should You Buy? - MarketBeat
When (RXRX) Moves Investors should Listen - Stock Traders Daily
Thinking about buying stock in BioNexus Gene Lab, Gladstone Inve - GuruFocus.com
Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One - Benzinga
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? - Inkl
2 Innovative Stocks That Could Deliver Outsize Returns - Yahoo! Voices
Recursion Announces Management Changes - Marketscreener.com
Recursion and Exscientia, two leaders in the AI drug - GlobeNewswire
Trans-Atlantic Triumph: AI Drug Pioneers Recursion, Exscientia Combine - Genetic Engineering & Biotechnology News
Cathie Wood's ARK makes major plays in Recursion, Twist Bioscience stock - Investing.com
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery - Markets Insider
RecursionNo News Isn't Good News When It Comes To Vanilla Pipeline (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals’ Strategic Acquisition and Leadership Changes - TipRanks
Recursion and Exscientia, Two Leaders in the AI Drug Discovery Space, Have Officially Combined to Advance the Industrialization of Drug Discovery - Wahanariau
Recursion Pharmaceuticals, Inc. - Via Ritzau
Recursion Pharmaceuticals stock hits 52-week low at $5.88 - Investing.com India
Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 1-Year LowHere's What Happened - MarketBeat
Recursion Pharmaceuticals CEO sells $301,800 in stock - Investing.com India
Recursion Pharmaceuticals director Blake Borgeson sells $87,457 in stock - Investing.com Canada
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.9% Following Insider Selling - MarketBeat
Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) - GuruFocus.com
Sumitomo Mitsui Trust Group Inc. Trims Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals CFO Michael Secora sells $229,504 in stock - Investing.com
Pier 88 Investment Partners LLC Acquires 109,210 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition - Investing.com
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition By Investing.com - Investing.com UK
Recursion, Exscientia shareholders back merger - Investing.com
Recursion and Exscientia Shareholders Approve the Proposed Combination - The Manila Times
Recursion & Exscientia Merger Approved: AI Drug Discovery Giants Set to Unite | RXRX Stock News - StockTitan
Recursion releases OpenPhenom-S/16 for microscopy data By Investing.com - Investing.com Australia
FMR LLC's Strategic Acquisition in Recursion Pharmaceuticals Inc - GuruFocus.com
Recursion releases OpenPhenom-S/16 for microscopy data - Investing.com
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden - GlobeNewswire
Recursion Pharmaceuticals, Inc. Announces the Release of OpenPhenom-S/16 in Google Cloud?s Model Garden - Marketscreener.com
Baillie Gifford & Co. Cuts Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Leerink Partnrs Issues Optimistic Estimate for RXRX Earnings - MarketBeat
Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week - Simply Wall St
Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - Yahoo Finance UK
ARK Investment Management LLC Boosts Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk - Simply Wall St
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals - Benzinga
Recursion Pharmaceuticals' (RXRX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Recursion Pharmaceuticals Reports Q3 2024 Earnings and Strategic Milestones - TipRanks
Recursion Pharmaceuticals: Q3 Earnings Snapshot - Barchart
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Recursion Pharmaceuticals Inc Cl A (RXRX-Q) QuotePress Release - The Globe and Mail
Is Recursion Pharmaceuticals a Millionaire-Maker Stock? - AOL
Recursion Pharmaceuticals Inc Azioni (RXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Recursion Pharmaceuticals Inc Azioni (RXRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gibson Christopher | Chief Executive Officer |
Nov 13 '24 |
Sale |
7.74 |
20,000 |
154,800 |
762,656 |
| Gibson Christopher | Chief Executive Officer |
Nov 14 '24 |
Sale |
7.35 |
20,000 |
147,000 |
762,656 |
| Borgeson Blake | Director |
Nov 12 '24 |
Sale |
7.64 |
11,447 |
87,457 |
7,066,113 |
| Secora Michael | Chief Financial Officer |
Nov 12 '24 |
Option Exercise |
2.22 |
39,375 |
87,413 |
1,490,256 |
| Secora Michael | Chief Financial Officer |
Nov 13 '24 |
Option Exercise |
2.22 |
39,375 |
87,413 |
1,514,631 |
| Secora Michael | Chief Financial Officer |
Nov 13 '24 |
Sale |
7.66 |
15,000 |
114,876 |
1,499,631 |
| Secora Michael | Chief Financial Officer |
Nov 12 '24 |
Sale |
7.64 |
15,000 |
114,628 |
1,475,256 |
1.09%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):